Omeros (OMER) Set to Announce Quarterly Earnings on Wednesday

Omeros (NASDAQ:OMER) is set to announce its earnings results after the market closes on Wednesday, August 7th.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13).

Omeros Trading Up 0.9 %

Shares of NASDAQ:OMER traded up $0.04 on Tuesday, hitting $4.39. The company had a trading volume of 273,190 shares, compared to its average volume of 457,558. The stock has a 50 day moving average price of $4.27 and a 200 day moving average price of $3.89. The stock has a market cap of $254.37 million, a price-to-earnings ratio of -2.25 and a beta of 1.45. Omeros has a 1-year low of $0.92 and a 1-year high of $5.68.

Wall Street Analyst Weigh In

Several research firms have weighed in on OMER. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Tuesday, June 4th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Tuesday, July 30th.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.